24/7 Market News Snapshot 10 July, 2025 – Cognition Therapeutics, Inc. Common Stock (NASDAQ:CGTX)

July 10, 2025

DENVER, Colo., 10 July, 2025 (www.247marketnews.com) – (NASDAQ:CGTX) are discussed in this article.
Cognition Therapeutics, Inc. (CGTX) has recently caught significant attention in the stock market, with shares skyrocketing by 66.07% to reach $0.884 during pre-market trading, up from the previous close of $0.532. This impressive gain is indicative of robust investor interest, reflected by a notable trading volume of 15.33 million shares. Market momentum is likely driven by positive sentiment surrounding the company’s innovative therapeutic solutions, particularly in light of recent developments.

The company’s trajectory was further bolstered by the successful conduct of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) concerning its lead compound, zervimesine (CT1812), aimed at treating Alzheimer’s disease. The meeting, which took place on July 9, 2025, focused on favorable results from the Phase 2 SHINE study, evaluating the safety, tolerability, and cognitive impacts of zervimesine in patients with mild-to-moderate Alzheimer’s.

Lisa Ricciardi, President and CEO, expressed optimism regarding the FDA discussions, emphasizing the potential pathway for zervimesine as a critical treatment option for Alzheimer’s patients. The company anticipates receiving formal feedback from the FDA in August, providing clarity on advancing to Phase 3 clinical trials necessary for a New Drug Application (NDA).

Zervimesine, an investigational oral therapy, targets central nervous system diseases by addressing the toxic protein accumulation that leads to cognitive decline. Initial outcomes from the SHINE study showed positive safety and tolerability results, along with early signs of cognitive improvement, highlighting the compound’s potential benefits for patients facing neurodegenerative disorders.

With a unique mechanism of action aimed at sigma-2 receptors, zervimesine presents a promising new avenue in the quest for effective treatments in a field that is continually seeking innovative solutions. Cognition Therapeutics remains dedicated to advancing its pipeline to deliver transformative health options for individuals and families affected by these challenging conditions.

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.